Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03714477
Other study ID # CRE 2018.276
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date October 30, 2022

Study information

Verified date February 2021
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Having the advantages of being minimally invasive and simple, extracorporeal shock wave lithotripsy (SWL) remains one of the treatment options for renal stones less than 2cm. Although SWL is the most minimally invasive surgical approach for stone, there are still some concern about its short and long term side effect. While, there are some evidences that SWL might lead to increase in new onset hypertension, investigator's recent study suggested it might also cause worsening of blood pressure control in patient with known hypertension. Therefore, further studies are needed to confirm the initial finding. This study recruits patients who have hypertension and are currently diagnosed to have renal stone and planned for SWL, in order to to investigate the effect of SWL on blood pressure control. After informed consent and background information have been obtained, patients will be randomized to either have routine SWL (treatment arm) or 6 months later (control arm). Group 1 patients will have blood pressure monitored for one day at home by an handy automated blood pressure measuring machine before SWL and 6 months after SWL. Group 2 patients will have blood pressure monitoring immediately and then 6 months later, just prior to the SWL.


Description:

BACKGROUND Extracorporeal shock wave lithotripsy (SWL) was first introduced in early 1980's for the management of urolithiasis. The advantage of being minimally invasive, when compared to other procedures for stone treatment, made SWL remain one of the treatment options for renal stones less than 2 cm in the latest guidelines. Despite considered as the most non-invasive treatment for urinary calculi, there are still many concerns about the long-term consequence of SWL. In particular, the effect of SWL on blood pressure is still a controversy topic. In the recent study, investigator has observed approximately 20% of subjects experienced worsened blood pressure control during the 2-year follow-up period, including 20/202 (9.95%) previously non-hypertensive subjects who developed new onset hypertension. The observed incidence of new-onset hypertension was quite similar those in some reported series. In the literature, there were multiple reports, including case series and hospital data analyses, 7-9 of development of new-onset hypertension after SWL. Unfortunately, most of those studies were retrospective and used different definitions of hypertension. But the high incidence of worsening blood pressure control, including 43 (36.4%) of 118 hypertensive subjects who required add-on antihypertensive therapies, observed in our study was alarming. Because most studies in the literature were just focused on development of new-onset hypertension, investigator's observation provides supplementary information about potential effects of SWL on pre-existing hypertension. In general, the average annual incidence of add-on pharmacotherapy among local hypertensive patients was 4.71-6.41%. 10 Therefore, the add-on therapy rate of 36.4% during the 2-year follow-up was much higher than that in the general population. Unfortunately, investigator did not include a non-interventional arm for comparison in the previous study and could not conclude that this outcome was solely attributable to SWL. Therefore, investigator would like to propose a prospective study to assess the effect SWL on the blood pressure control in patients with known hypertension. Investigator hope the study results will provide additional information on the long-term effect of SWL on patients. OJECTIVES To investigate the effect of extracorporeal shockwave lithotripsy on the effect of change in blood pressure in patients with known hypertension. STUDY PROTOCOL: Patients fulfilled the inclusion and exclusion criteria specific to this study will be prospectively recruited. After obtaining informed consent, patients will be randomized to either treatment group or control group. Baseline information, including age, years of diagnosed to have hypertension, current medical usage, other comorbidities, BMI etc. will be collected from patients. All SWL would be performed in the Lithotripsy and Uro-investigation Centre of the Prince of Wales Hospital, and treated by Modulith SLX-F2 Connect (Storz Medical, Switzerland), an electromagnetic lithotriptor. The treatment would be performed as standard care in our hospital. After SWL, the patient would be follow-up in clinic as usual. During the 6 months study period, patients are strongly advised to avoid change in hypertensive medication. Blood pressure assessment: During each blood pressure assessment, the following procedure will be performed: 1. 24-hour blood pressure monitoring - 24-h non-invasive ambulatory BP and HR monitoring was performed using a validated device and followed the recommended approached. 11 The blood pressure measurement would be programmed to measure BP every 15 min. Each recording will be started in the morning and performed throughout a full 24-h period, during which subjects are allowed to follow their normal daily routine. The analysis of 24-h BP recordings are preceded by removal of artifacts, according to previously described editing criteria. 12 Recordings are excluded from the analysis when > 10% of all readings or more than one reading per hour is missed. Computed analysis of the individual recordings provided 24-h, night-time (23.00-07.00 h), morning-time (0.7.00-12.00 h), and afternoon/evening-time (12.00- 23.00 h) mean values of SBP, DBP, and HR. 2. Clinic blood pressure measurement At each visit, blood pressure will be measured after patient rested for more than 10 minutes, with repeated measurement 5 minutes apart. The mean blood pressure will be recorded. 3. Any changes in antihypertensive drugs and reasons 4. Any adverse events. The result collected will be used for further analysis


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 30, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Renal calculi of size 5-15 mm in maximal diameter and considered as suitable for SWL - Patient with known hypertension and on regular medical treatment with regular follow-up. - Patient with stable hypertension for at least 3 months Exclusion Criteria: - Patients had previous SWL, kidney surgery, percutaneous nephrolithotomy, etc. - Patients with stones obviously required more than one section of SWL

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Extracorporeal shock wave lithotripsy
A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.

Locations

Country Name City State
Hong Kong Prince of Wales Hospital Shatin

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary The changes in mean 24hr systolic and diastolic blood pressure measurement For treatment arm, the changes in mean 24hr systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean 24hr systolic and diastolic blood pressure measurement right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean night time diastolic and systolic blood pressure For treatment arm, the changes in mean night time systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean night time systolic and diastolic blood pressure measurement right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean night time heart rate For treatment arm, the changes in mean heart rate before SWL and 6 monthes after SWL For control arm, the changes in mean night time heart rate right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean morning-time diastolic and systolic blood pressure For treatment arm, the changes in mean morning-time systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean morning-time systolic and diastolic blood pressure measurement right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean morning-time heart rate For treatment arm, the changes in mean morning-time heart rate before SWL and 6 monthes after SWL For control arm, the changes in mean morning-time heart rate right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean afternoon/evening diastolic and systolic blood pressure For treatment arm, the changes in mean afternoon/evening systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean afternoon/evening systolic and diastolic blood pressure measurement right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean afternoon/evening heart rate For treatment arm, the changes in mean afternoon/evening heart rate before SWL and 6 monthes after SWL For control arm, the changes in mean afternoon/evening heart rate right after randomization and in 6 months. Baseline, 6 months
Secondary Change in mean 24hr heart rate For treatment arm, the changes in mean 24hr heart rate measurement before SWL and 6 monthes after SWL For control arm, the changes in mean 24hr heart rate measurement right after randomization and in 6 months. Baseline, 6 months
Secondary The need of add-on therapy for hypertension Any add-on anti-hypertensive drugs in 6 months time 6 months
Secondary Any adverse effects after SWL Any adverse effects comparing the treatment arm and control arm during study period 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A